On 5 August 2013, orphan designation (EU/3/13/1185) was granted by the European Commission to Alexion Europe SAS, France, for eculizumab for the treatment of neuromyelitis optica.
- What is neuromyelitis optica?
Neuromyelitis optica is an inflammatory disease of the optic nerve and the spinal cord that can lead to the reduction or loss of vision, loss of sensation, bladder dysfunction, weakness and paralysis of the arms and legs.
The cause of the disease is not known but it is thought to involve the complement system, a group of proteins in the blood that help the immune system (the body’s natural defences) to fight infections. In patients with neuromyelitis optica, the complement system gets activated and results in damage to the nerve cells.
Neuromyelitis optica is a debilitating disease that can be life threatening due to damage to the nervous system function.
- What is the estimated number of patients by the condition?
At the time of designation, neuromyelitis optica affected approximately 0.4 in 10,000 people in the European Union (EU). This was equivalent to a total of around 20,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. This represents a population of 509,000,000 (Eurostat 2013).
- What treatments are available?
At the time of designation, no satisfactory methods were authorised in the EU for the treatment of neuromyelitis optica. Treatments for this disease were aimed at reducing inflammation. They included glucocorticoids, immunosuppressants and plasmapheresis, also called plasma exchange (or passage of the blood plasma through a filter).
- How is this medicine expected to work?
Eculizumab is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific structure (called an antigen) that is found in the body. In patients with neuromyelitis optica, eculizumab is expected to attach to the C5 complement protein. By attaching and blocking the C5 complement protein, eculizumab prevents the complement system activation, thereby reducing the damage to nerve cells and relieving the symptoms of the disease.
- What is the stage of development of this medicine?
The effects of eculizumab have been evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials with eculizumab in patients with neuromyelitis optica were planned.
At the time of submission, eculizumab was authorised in the EU for paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome. At the time of submission, it was not authorised anywhere in the EU for neuromyelitis optica or designated as an orphan medicinal product elsewhere for this condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 11 July 2013 recommending the granting of this designation.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/13/1185: Public summary of opinion on orphan designation: Eculizumab for the treatment of neuromyelitis optica||(English only)||16/09/2013|
|Disease/condition||Treatment of neuromyelitis optica|
|Date of decision||05/08/2013|
|Orphan decision number||EU/3/13/1185|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor’s contact details
Alexion Europe SAS
25 boulevard de l’Amiral Bruix
Tel. +33 153 6438 00
Fax +33 153 6438 20
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.